Biotech Values

[DewDiligence]

IMRA terminates all clinical programs—lays_off_all_but_6_employees:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001672619/000156459022014494/imra-8k_20220405.htm

On April 12, 2022, the Board of Directors (“Board”) of IMARA Inc. (the “Company”) approved a reduction of the Company’s workforce (the “Workforce Reduction”) by approximately 83% across all areas of the Company, to a total of six remaining full-time employees.

The Workforce Reduction follows the Company’s decision, further described below, to discontinue development of tovinontrine (IMR-687) in sickle cell disease, beta-thalassemia and heart failure with preserved ejection fraction, as well to discontinue its development plans with respect to IMR-261.

The Workforce Reduction is expected to be substantially completed by the end of the second quarter of 2022. The Workforce Reduction is designed to substantially reduce the Company’s operating expenses while the Company undertakes a comprehensive assessment of its strategic options to maximize shareholder value.